gemcitabine has been researched along with bryostatin 1 in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (50.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Armand, JP | 1 |
| Dent, P; Grant, S; Kramer, LB; Povirk, LF; Saunders, AM; Vrana, JA; Zhang, XF | 1 |
| Adsay, V; Al-Katib, AM; Li, Y; Mohamed, AN; Mohammad, RM; Pettit, GR; Sarkar, FH; Vaitkevicius, VK | 1 |
| Ali, S; Aranha, O; Li, Y; Pettit, GR; Philip, PA; Sarkar, FH | 1 |
| El-Rayes, BF; Gadgeel, S; Lorusso, P; Manza, S; Philip, PA; Shields, AF | 1 |
| Ali, S; El-Rayes, BF; Philip, PA; Sarkar, FH | 1 |
1 review(s) available for gemcitabine and bryostatin 1
| Article | Year |
|---|---|
New anticancer drugs in Europe.
Topics: Aminopterin; Anthraquinones; Antimetabolites, Antineoplastic; Antineoplastic Agents; Antineoplastic Agents, Alkylating; Aziridines; Bridged-Ring Compounds; Bryostatins; Camptothecin; Dacarbazine; Deoxycytidine; Distamycins; Doxorubicin; Europe; Gemcitabine; Humans; Indolequinones; Indoles; Irinotecan; Lactones; Macrolides; Nitrogen Mustard Compounds; Nitrosourea Compounds; Pyrazoles; Quinazolines; Taxoids; Temozolomide; Thiophenes; Vinca Alkaloids | 1997 |
1 trial(s) available for gemcitabine and bryostatin 1
| Article | Year |
|---|---|
Phase I study of bryostatin 1 and gemcitabine.
Topics: Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Deoxycytidine; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Gemcitabine; Humans; Injections, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasms; Treatment Outcome | 2006 |
4 other study(ies) available for gemcitabine and bryostatin 1
| Article | Year |
|---|---|
Inhibition of protein kinase C activator-mediated induction of p21CIP1 and p27KIP1 by deoxycytidine analogs in human leukemia cells: relationship to apoptosis and differentiation.
Topics: Antimetabolites, Antineoplastic; Apoptosis; Bryostatins; Cell Cycle Proteins; Cell Differentiation; Cyclin-Dependent Kinase Inhibitor p21; Cyclin-Dependent Kinase Inhibitor p27; Cyclins; Cytarabine; Deoxycytidine; Drug Interactions; Enzyme Activation; Gemcitabine; Humans; Lactones; Leukemia; Macrolides; Microtubule-Associated Proteins; Mitogens; Protein Kinase C; Tetradecanoylphorbol Acetate; Tumor Suppressor Proteins; U937 Cells | 1999 |
Clonal preservation of human pancreatic cell line derived from primary pancreatic adenocarcinoma.
Topics: Adenocarcinoma; Aged; Animals; Antineoplastic Agents; Bryostatins; Deoxycytidine; DNA Mutational Analysis; Ethers, Cyclic; Gemcitabine; Genes, p53; Genes, ras; Humans; Karyotyping; Lactones; Macrolides; Male; Mice; Mice, SCID; Neoplasm Transplantation; Oligopeptides; Pancreatic Neoplasms; Tumor Cells, Cultured | 1999 |
Sensitization of human breast cancer cells to gemcitabine by the protein kinase C modulator bryostatin 1.
Topics: Antineoplastic Agents; Apoptosis; Breast Neoplasms; Bryostatins; Cell Survival; Cytosol; Deoxycytidine; Drug Synergism; Enzyme Inhibitors; Enzyme-Linked Immunosorbent Assay; Female; Flow Cytometry; Gemcitabine; Humans; Isoenzymes; Lactones; Macrolides; Protein Kinase C; Tumor Cells, Cultured | 2003 |
Protein kinase C: a target for therapy in pancreatic cancer.
Topics: Adenocarcinoma; Adenoma; Antineoplastic Combined Chemotherapy Protocols; Bryostatins; Cell Survival; Deoxycytidine; Gemcitabine; Humans; Isoenzymes; Pancreatic Neoplasms; Protein Kinase C; Protein Kinase Inhibitors; Reference Values | 2008 |